Literature DB >> 12687015

RRM1-induced metastasis suppression through PTEN-regulated pathways.

Ashish Gautam1, Zhan-Rong Li, Gerold Bepler.   

Abstract

Lung cancer is the leading cause of cancer-related mortality in the United States. Only 15% of patients with this disease survive 5 years or longer. Early metastatic spread is the single most important reason for this poor outcome. The survival of patients with pathological stage I disease, that is, no evidence for metastatic spread, and molecular aberrations on chromosome 11p15.5 is equal to that of patients with stage II disease, that is, metastatic spread to hilar lymph nodes. RRM1 is a gene in this region, and it is haploinsufficient in at least 34% stage I patients. Here, we show that overexpression of RRM1 in human and mouse lung cancer cell lines induced PTEN expression, reduced phosphorylation of focal adhesion kinase (FAK), suppressed migration, invasion, and metastasis formation, and increased survival in an animal model. Increased PTEN expression was required for the RRM1-induced suppression of cell motility and FAK phosphorylation. We conclude that RRM1 functions as a metastasis suppressor gene through induction of PTEN expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687015     DOI: 10.1038/sj.onc.1206232

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

1.  Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.

Authors:  Lauren C Harshman; Gerold Bepler; Zhong Zheng; John P Higgins; Genevera I Allen; Sandy Srinivas
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

2.  p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Francesca Cottini; Yoshihisa Nozawa; Hyuk-Soo Seo; Hiroto Ohguchi; Mehmet K Samur; Diana Cirstea; Naoya Mimura; Yoshikazu Iwasawa; Paul G Richardson; Nikhil C Munshi; Dharminder Chauhan; Walter Massefski; Teruhiro Utsugi; Sirano Dhe-Paganon; Kenneth C Anderson
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

Review 3.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

Review 4.  Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.

Authors:  Simona Carnio; Silvia Novello; Mauro Papotti; Marco Loiacono; Giorgio Vittorio Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2013-10

5.  A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

Authors:  Anne M Traynor; Ju-Whei Lee; Gerald K Bayer; John M Tate; Sachdev P Thomas; Miroslaw Mazurczak; David L Graham; Jill M Kolesar; Joan H Schiller
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

6.  Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.

Authors:  Wen Liu; Carolyn J Vivian; Amanda E Brinker; Kelsey R Hampton; Evi Lianidou; Danny R Welch
Journal:  Cancer Microenviron       Date:  2014-06-18

7.  Nicotine promotes tumor growth and metastasis in mouse models of lung cancer.

Authors:  Rebecca Davis; Wasia Rizwani; Sarmistha Banerjee; Michelle Kovacs; Eric Haura; Domenico Coppola; Srikumar Chellappan
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

8.  RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Authors:  Song Dong; Ai-Lin Guo; Zhi-Hong Chen; Zhen Wang; Xu-Chao Zhang; Ying Huang; Zhi Xie; Hong-Hong Yan; Hua Cheng; Yi-Long Wu
Journal:  J Hematol Oncol       Date:  2010-03-13       Impact factor: 17.388

9.  Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines.

Authors:  Jun Zhou; Paula Oliveira; Xueli Li; Zhengming Chen; Gerold Bepler
Journal:  J Nucleic Acids       Date:  2010-09-28

10.  Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.

Authors:  Keqiang Zhang; Shuya Hu; Jun Wu; Linling Chen; Jianming Lu; Xiaochen Wang; Xiyong Liu; Bingsen Zhou; Yun Yen
Journal:  Mol Cancer       Date:  2009-02-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.